01 July 2022
: Case report 
Adalimumab Mitigates Lumbar Radiculopathy in a Case of Ankylosing Spondylitis
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare coexistence of disease or pathology
Trevor Persaud1ABCDEFG*, Richard Morgan
1ABCDEFG, Hein Linn Thant1ABCDEFG, Francis J. DeAsis 1ABCDEFG, Felix Ferre1DEFG, Jose Diaz 1BDEF
DOI: 10.12659/AJCR.936600
Am J Case Rep 2022; 23:e936600
Table 2. Patient’s laboratory tests summary (obtained on initial visit).
| Test | Result | Reference range |
|---|---|---|
| Completement, total | >60 | 31–60 U/mL |
| Completement component C3 | 156 | 82–185 mg/dL |
| Completement component C4 | 36 | 15–53 mg/dL |
| Rheumatoid factor | <14 | <14 IU/mL |
| C-reactive protein | 2.2 | <8.0 mg/L |
| Sjogren’s antibody (SS-A) | <1.0 NEG | <1.0 NEG |
| Sjogren’s antibody (SS-B) | <1.0 NEG | <1.0 NEG |
| Proteinase-3 antibody | <1.0 (no antibody detected | <1.0 |
| Myeloperoxidase antibody | <1.0 (no antibody detected) | <1.0 |
| HLA-B27 antigen | 6.9 (Negative) | 5.0–11.0 mcg/mL |
| ANA screen, IFA | Negative | Negative |
| HIV antigen/antibody, 4 generation | Non-reactive | Non-reactive |
| Hepatitis C antibody | Non-reactive | Non-reactive |
| Cyclic citrullinated peptide antibody | <16 (negative) | <20 |
| VDRL | Non-Reactive | Non-reactive |
| Red blood cell count | 4.18 | 4.20–5.80 Million/uL |
| Hemoglobin | 12.7 | 13.2–17.1 g/dL |
| Hematocrit | 35.4 | 38.5–50.0% |
| Glucose | 115 | 65–99 mg/dL |
| SS-A – anti-Sjogren’s-syndrome-related antigen A autoantibodies; SSB – anti-Sjögren’s-syndrome-related antigen B autoantibodies; HLA – human leukocyte antigens; ANA – antinuclear antibodies; IFA – immunofluorescence assay; HIV – human immunodeficiency virus; VDRL – venereal disease research laboratory test. | ||